Literature DB >> 12058967

Sensitivity of p53-deficient cells to oxaliplatin and thio-TEPA (N, N', N" triethylenethiophosphoramide).

Young R Seo1, Edmund I-T Chen, Martin L Smith.   

Abstract

P53 is known as a determinant of cellular responses to DNA damage, including apoptosis, cell cycle arrest, and DNA repair. Its role is most easily understood in the context of Burkitt lymphoma and other apoptosis-prone cell types. A number of epithelial cancer cell types, by contrast, exhibit a higher threshold for apoptosis induction in response to DNA damage. In fact, p53 mediates DNA repair and protective responses in the latter cell types, in some cases p53-deficient cells being more sensitive to DNA damage, antithetical to the situation in Burkitt lymphoma and other apoptosis-prone cell types. Ultraviolet light, cisplatin, and nitrogen mustards produce damage that is repaired by a p53-regulated pathway. Here, we explore the sensitivity of the platinum compound oxaliplatin and thio-TEPA (N, N', N", triethylenethiophosphoramide), a cancer chemotherapeutic agent that produces largely base damage, in p53-defective cells. This work demonstrates that the contribution of p53 temporally correlates with DNA repair pathways to produce a resistant phenotype, while the p53-defective cells are more sensitive to certain DNA-damaging chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12058967     DOI: 10.1023/a:1014913708916

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  3 in total

1.  The "Two faces" of Tumor Suppressor p53-revisited.

Authors:  Martin L Smith; M A Suresh Kumar
Journal:  Mol Cell Pharmacol       Date:  2010-01-01

2.  Oxaliplatin-loaded nanoemulsion containing Teucrium polium L. essential oil induces apoptosis in Colon cancer cell lines through ROS-mediated pathway.

Authors:  Waad A Al-Otaibi; Sahar M AlMotwaa
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

3.  Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells.

Authors:  D Arango; A J Wilson; Q Shi; G A Corner; M J Arañes; C Nicholas; M Lesser; J M Mariadason; L H Augenlicht
Journal:  Br J Cancer       Date:  2004-11-29       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.